01

Upadacitinib Clears Refractory ARPC After Dupilumab Failure

Upadacitinib 15 mg daily cleared refractory ARPC in a stage 4 CKD patient after dupilumab triggered paradoxical worsening within 24 hours; remission held at 1-year follow-up.